Learn how 1536-well whole-transcriptome profiling, combined with Arctoris’ automated Ulysses® platform, can support reproducible, high-throughput compound profiling and perturbation dataset generation.
Drug discovery teams are increasingly working across larger combinations of compounds, doses, timepoints, cell models, and assay formats. To support confident decision-making and AI-enabled discovery, biological datasets need to be scalable, standardised, and rich enough to connect compounds to mechanism, toxicity, and cellular response.
In this on-demand webinar, Alithea Genomics introduces MERCURIUS™ 1536 DRUG-seq, a high-throughput whole-transcriptome profiling workflow designed to generate compound-response datasets at screening scale.
Arctoris shares how automated experimental execution with Ulysses® supports the upstream workflow, including cell preparation, compound dosing, cell seeding, viability assessment, plate handling, and sample preparation in 1536-well format.
Watch the recording to learn how 1536 DRUG-seq and automated workflow execution can help discovery teams generate reliable, AI-ready perturbation datasets at scale.
What you will learn:
• Bring whole transcriptome profiling into 1536-well screening workflows
• Build large-scale perturbation datasets across compounds, doses, cell models, and conditions
• Reduce plate count, cost per profile, and batch burden compared with lower-density formats
• Link compounds to biological response at a scale suited to modern screening and AI/ML workflows
• Understand how automated cell preparation, compound treatment, and sample preparation with Ulysses® support reproducible 1536-well transcriptomic screening
• Learn why standardised experimental execution is critical for generating AI-ready perturbation datasets
• See real case studies and data generated with Arctoris' Automated Ulysses® platform and MERCURIUS™ 1536 DRUG-seq
Speakers
Riccardo Dainese
CBO and Co-founder, Alithea Genomics
Maya Wilson
Senior Scientist in Screening & Automation, Arctoris